Browse studies

Find your next paid study

8 recruiting studies matching your filters

A Phase I Trial of Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

To determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-1…

Hematologic Diseases

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT07701889

Observational

Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs…

LeukemiaAcute Myeloid Leukemia in RemissionMyelodysplasia+10 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT05794880

Observational

Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared t…

LeukemiaMyelomaMyelodysplastic Syndromes+3 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06487247

Observational

Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Related or Unrelated Donor After TCR αβ+T Cells/CD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological Disorders

The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unre…

Hematologic Diseases

Estimated

~$10 – $7,500

Alice BertainaNCT04249830

Phase 1

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cel…

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more

Estimated

~$10 – $8,750

OriCell Therapeutics Co., Ltd.NCT06271252

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research

Hematologic Diseases

Estimated

~$10 – $1,050

Invivoscribe, Inc.NCT06222164

Phase 3

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will eval…

Beta-ThalassemiaThalassemiaHematologic Diseases+4 more

Estimated

~$10 – $8,750

Vertex Pharmaceuticals IncorporatedNCT05477563

Phase 1

Phase 1/1b Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR αβ+ T-cell/ CD19+ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (αβ Depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies

The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune rec…

Hematologic Diseases

Estimated

~$10 – $7,500

Porteus, Matthew, MDNCT04640987